Ignite Creation Date:
2024-05-06 @ 2:48 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04431479
Status:
RECRUITING
Last Update Posted:
2024-03-26
First Post:
2020-06-11
Brief Title:
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD PQRST Study
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Fred Hutchinson Cancer Center
Study Overview
Official Title:
Predicting the Quality of Response to Specific Treatments PQRST
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease cGVHD who are about to start initial or second-line therapy Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response
Detailed Description:
OUTLINE
Patients complete questionnaires over 10 minutes about physical symptoms activity level and emotional well-being and have their medical records reviewed at baseline 1 3 and 6 months after starting index treatment and at start of a new systemic treatment Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment or at a treatment change visit if new therapy has not started
Patients complete questionnaires over 10 minutes about physical symptoms activity level and emotional well-being and have their medical records reviewed at baseline 1 3 and 6 months after starting index treatment and at start of a new systemic treatment Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment or at a treatment change visit if new therapy has not started
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2020-01242 | REGISTRY | None | None |
| 10360 | OTHER | None | None |
| R01CA118953 | NIH | Fred HutchUniversity of Washington Cancer Consortium | httpsreporternihgovquickSearchR01CA118953 |